

Karolina Andersson Sundell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8626647/publications.pdf>

Version: 2024-02-01

48
papers

892
citations

471509

17
h-index

501196

28
g-index

48
all docs

48
docs citations

48
times ranked

1547
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of The High risk and unmet Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107859.	2.3	2
2	Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 561-567.	1.6	1
3	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , 2020, 43, 24-32.	1.8	18
4	Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00133.	2.4	6
5	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , 2020, 311, 7-14.	1.7	9
6	Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000719.	2.8	7
7	ASSESSMENT OF THE HIGH RISK AND UNMET NEED IN PATIENTS WITH CAD AND TYPE 2 DIABETES (ATHENA): US BURDEN OF ILLNESS IN A COMMERCIALY-INSURED POPULATION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 38.	2.8	0
8	Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000639.	2.8	10
9	USE OF EVIDENCE-BASED PREVENTIVE MEDICAL THERAPIES 1-3 YEARS POST-MYOCARDIAL INFARCTION IN THE PROSPECTIVE GLOBAL TIGRIS REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 169.	2.8	0
10	ASSESSMENT OF THE HIGH RISK AND UNMET NEED IN PATIENTS WITH CAD AND TYPE 2 DIABETES (ATHENA): US BURDEN OF ILLNESS IN THE DIABETES COLLABORATIVE REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 39.	2.8	0
11	Attitudes towards sales and use of over-the-counter drugs in Sweden in a reregulated pharmacy market: a population-based study. <i>International Journal of Pharmacy Practice</i> , 2019, 27, 17-24.	0.6	15
12	Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study. <i>BMJ Open</i> , 2018, 8, e020309.	1.9	19
13	Antidepressants and suicidal behaviour in late life: a prospective population-based study of use patterns in new users aged 75 and above. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 201-208.	1.9	10
14	Late-life suicidal behaviours among new users of antidepressants: a prospective population-based study of sociodemographic and gender factors in those aged 75 and above. <i>BMJ Open</i> , 2018, 8, e022703.	1.9	7
15	Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register. <i>BMC Health Services Research</i> , 2018, 18, 900.	2.2	10
16	Impact of new efficacy information on sales of antihypertensive medicines in Japan and Sweden. <i>Health Policy and Technology</i> , 2018, 7, 194-199.	2.5	3
17	Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: A nation-wide register-based study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1220-1232.	1.9	10
18	Direct and indirect costs for adverse drug events identified in medical records across care levels, and their distribution among payers. <i>Research in Social and Administrative Pharmacy</i> , 2017, 13, 1151-1158.	3.0	4

#	ARTICLE	IF	CITATIONS
19	Adherence to antidepressants among women and men described with trajectory models: a Swedish longitudinal study. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1381-1389.	1.9	9
20	Beliefs about medicines are strongly associated with medicine-use patterns among the general population. <i>International Journal of Clinical Practice</i> , 2016, 70, 277-285.	1.7	34
21	Consumer preferences for over-the-counter drug retailers in the reregulated Swedish pharmacy market. <i>Health Policy</i> , 2016, 120, 327-333.	3.0	18
22	Comparison of pharmaceutical policies to stimulate use of generics in Japan and Sweden. <i>Health Policy and Technology</i> , 2016, 5, 189-195.	2.5	3
23	Refill Adherence in Relation to Substitution and the Use of Multiple Medications: A Nationwide Population Based Study on New ACE-Inhibitor Users. <i>PLoS ONE</i> , 2016, 11, e0155465.	2.5	1
24	Pharmacoepidemiology at Nordic School of Public Health NHV: Examples from 1999 to 2014. <i>Scandinavian Journal of Public Health</i> , 2015, 43, 73-80.	2.3	1
25	Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR). <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000059.	2.8	17
26	Trust, reciprocity and collective action to fight antibiotic resistance. An experimental approach. <i>Social Science and Medicine</i> , 2015, 142, 249-255.	3.8	22
27	Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?. <i>PLoS ONE</i> , 2015, 10, e0137451.	2.5	45
28	Is the level of patient co-payment for medicines associated with refill adherence in Sweden?. <i>European Journal of Public Health</i> , 2014, 24, 85-90.	0.3	18
29	Prevalence, nature and potential preventability of adverse drug events – a population-based medical record study of 4970 adults. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 170-183.	2.4	58
30	Effects of generic substitution on refill adherence to statin therapy: a nationwide population-based study. <i>BMC Health Services Research</i> , 2014, 14, 626.	2.2	13
31	Influence of refill adherence method when comparing level of adherence for different dosing regimens. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 589-597.	1.9	8
32	Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. <i>BMJ Open</i> , 2013, 3, e002574.	1.9	38
33	Socio-economic determinants of early discontinuation of anti-depressant treatment in young adults. <i>European Journal of Public Health</i> , 2013, 23, 433-440.	0.3	19
34	Factors associated with switching and combination use of antidepressants in young Swedish adults. <i>International Journal of Clinical Practice</i> , 2013, 67, 1302-1310.	1.7	4
35	The Nordic prescription databases as a resource for pharmacoepidemiological research – a literature review. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 691-699.	1.9	156
36	Refill adherence and self-reported adverse drug reactions and subtherapeutic effects: a population-based study. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1317-1325.	1.9	6

#	ARTICLE	IF	CITATIONS
37	Prevalence and Perceived Preventability of Self-Reported Adverse Drug Events – A Population-Based Survey of 7099 Adults. PLoS ONE, 2013, 8, e73166.	2.5	37
38	Methods for Assessing the Preventability of Adverse Drug Events. Drug Safety, 2012, 35, 105-126.	3.2	43
39	PHP74 Cost-of-Illness of Patient-Reported Adverse Drug Events – a Population-Based Survey. Value in Health, 2012, 15, A301-A302.	0.3	1
40	PMH7 Analyses of Switching and Combination Use of Antidepressants in Young Swedish Adults. Value in Health, 2012, 15, A334.	0.3	0
41	Modelling drug-related morbidity in Sweden using an expert panel of pharmacists™. International Journal of Clinical Pharmacy, 2012, 34, 538-546.	2.1	10
42	Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. Diabetes, Obesity and Metabolism, 2012, 14, 717-726.	4.4	24
43	PHP60 Drug-related Morbidity – Modeling the Cost-of-Illness in Sweden Using Pharmacists' Opinion. Value in Health, 2011, 14, A344.	0.3	0
44	Antidepressant utilization patterns and mortality in Swedish men and women aged 20–34 years. European Journal of Clinical Pharmacology, 2011, 67, 169-178.	1.9	19
45	A comparison of two methods for estimating refill adherence to statins in Sweden: the RARE project. Pharmacoepidemiology and Drug Safety, 2011, 20, 1073-1079.	1.9	30
46	Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus – An Observational Study from the Swedish National Diabetes Register. PLoS ONE, 2011, 6, e18744.	2.5	26
47	A comparative analysis of remuneration models for pharmaceutical professional services. Health Policy, 2010, 95, 1-9.	3.0	37
48	Impact of a generic substitution reform on patients™ and society's expenditure for pharmaceuticals. Health Policy, 2007, 81, 376-384.	3.0	64